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Liposomes have been widely used to deliver antigens to the antigen-presenting cells (APCs) and also to
modify their immunological behaviour in model animals. We recently demonstrated the potential of yeast
lipid liposomes to undergo membrane–membrane fusion with cytoplasmic membrane of the target cells.
Interestingly, studies in the present report revealed that antigen encapsulated in yeast lipid liposomes could
be successfully delivered simultaneously into the cytosolic as well as endosomal processing pathways of
APCs, leading to the generation of both CD41 T helper and CD81 cytotoxic T cells. In contrast,
encapsulation of same antigen in egg phosphatidyl-choline (PC) liposomes, just like its free form, has
inefficient access to the cytosolic pathway of major histocompatibility complex (MHC) I dependent antigen
presentation and failed to generate antigen specific CD81 cytotoxic T-cell response. However, both egg PC
as well as yeast lipid liposomes have elicited strong antigen specific antibody responses in immunized
animals. These results imply usage of liposome encapsulated antigen as potential candidate vaccine capable
of eliciting both cell mediated as well as humoral immune responses.
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INTRODUCTION
The protein antigens delivered to APCs, normally undergo
processing within the endosomes to produce the peptides that
bind to MHC class-II molecules. The MHC II processing and
presentation of the antigen results in the activation of CD41 T
cells [1, 2]. On the other hand, CD81 T cell responses can be
elicited by the endogenous antigens, which are processed within
the cytosol and produce peptides, which bind to MHC-I
molecules [2]. Nevertheless, exogenous antigen can also enter
the class I processing pathway, if it is delivered in a vehicle that
can fuse either with the plasma membrane under normal
physiological conditions or with the endosomal membrane at
low pH [2–4, 16, 17]. Since both cytotoxic as well as T-helper
cells are crucial for protecting the host against intracellular
pathogens to mount an effective immunity against such
infections, it is important to develop vaccines that generate
strong CD41 and CD81 T-cell responses [5–7].
In our previous study, we isolated the fusogenic lipids from
yeast cells and utilized them for the first time to prepare
liposomes [8]. We demonstrated that the yeast lipid liposomes
very effectively fuse with the membrane of macrophages. In the
present report we established that antigen encapsulated in the
liposomes could be readily introduced into the cytoplasmic as
well as endosomal compartments of the target cells. Moreover,
these studies have revealed that antigen entrapped in these
liposomes could generate strong OVA-specific, CD41 T helper
as well as CD81 cytotoxic T cells. The T-helper response was
chiefly of Th-2 type, as evidenced by the secretion of interleukin
(IL)-4 and immunglobulin (Ig)G1-isotype [9]. On the contrary,
the same antigen after encapsulation in egg PC liposomes was
able to induce humoral immune response mainly.
MATERIALS AND METHODS
Animals. Inbred female BALB/c mice (8–10-weeks-old), of 20 ^ 2 g
of weight, were obtained from the Institute’s Animal House Facility.
Chemicals and reagents. Egg PC was prepared using the standard
method [10]. Cholesterol (chol) was purchased from Centron Research
Laboratory, Mumbai, India. Ovalbumin (OVA) was from Sigma
Chemical Company (St. Louis, MO, USA). Antibodies to IL-2 (HB
8794), IL-2 receptors (CRL 1698 and TIB 222), IAd (MKD6), Mac 2
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(TIB 166), L3T4 (GK1.5), lyt 2.2 (TIB 210) and IL-4 (11B11) were
used as culture supernatants of the hybridomas. The P815 cells, an
MHC matched (H-2d) mastocytoma cell line, EL-4 cells, an MHC
disparate (H-2b) lymphoma cell line, HT-2 cell line (CRL-1841) and
hybridomas used in the study were procured from ATCC (Rockville,
MD, USA). [3H]-thymidine and [51Cr] sodium-chromate were bought
from Bhabha Atomic Research Center, Mumbai, India.
Preparation of liposomes. The yeast lipid was isolated from
Saccharomyces cerevisiae cells as described elsewhere [8]. The
liposomes were prepared essentially by following the published
procedure [11]. Briefly, egg PC/cholesterol (2 : 1 molar ratio, total
20 mg) or yeast lipids (20 mg) were reduced to thin dry film. The film
was hydrated followed by sonication in a bath-type sonicator for 2 h at
4 8C, under N2 atmosphere. The liposomes thus formed were mixed at
this stage with an equal volume of OVA (30 mg/ml). The mixture was
flash frozen and thawed (3 cycles), and then lyophilized. The free-
flowing, dried powder obtained was rehydrated with distilled water
(120 ml) and finally re-constituted with phosphate-buffered saline
(PBS). The preparation was centrifuged at 14 000  g and the pellet
was further washed at least 3 times with PBS to remove the traces of the
unentrapped solute. The protein entrapped in the liposomes was
estimated as described elsewhere [8]. Briefly, the liposomes (given
volume) were lysed with 10% Triton X-100 solution (the final
concentration of Triton X-100 was maintained 1%). The mixture of
solutions A and B of the Bicichoninic acid (BCA) reagent was added to
the lysed liposomes (released protein) and then incubated at 37 8C for
45 min. The absorbance was measured at 570 nm wavelength. The
protein concentration was calculated using a standard curve of OVA
plotted in the presence of Triton X-100.
Immunization. The immunological studies were performed in inbred
female BALB/c mice. Each group was consisted of five animals. The
animals were immunized with different preparations (free OVA or
entrapped in liposomes) of antigen on various days. The following
immunizing schedules were adapted for administration of OVA into the
animals, for different immunological studies.
Cell preparation. (a) CD81 T cells. Different groups of BALB/c mice
were injected separately, through an intravenous route, with a total of
three doses (day 0, 7, and 14) of free OVA, OVA encapsulated in egg
PC/chol or yeast lipids liposomes and also with free OVA mixed with
empty liposomes [100 mg OVA (which correspond to 500 nmoles of
lipid)/animal/week] for 3 weeks. On day 21, the animals (five animals
each group) were sacrificed and spleens were removed aseptically. The
cells were prepared as described elsewhere [12]. The cells obtained
from different animals in a given group were pooled, purified and used
in cytotoxicity assay. The enriched population stained with anti-CD8
antibodies (Ab), was . 98% pure, as evaluated by FACScan.
(b) CD41 T cells. Animals were immunized with single dose of free
OVA, OVA encapsulated in egg PC/chol or yeast-lipid liposomes
(100 mg OVA/animal) through intravenous route. On day 7, the animals
(five animals each group) were sacrificed and their spleens were
removed aseptically and CD41 T cells were isolated as described
elsewhere [12]. For lymphokine assay experiments, the animals were
immunized intravenously using two different immunizing schedules. In
one set, the animals (five animals each group) were immunized with
single dose of OVA (100 mg OVA/animal), while in another set, the
animal were immunized with total three doses of OVA (100 mg OVA
per animal, on day 0, 7, and 14). On day 21, the animals were sacrificed
and CD41 T cells were isolated as described above. The enriched
population of CD41 T cells were stained with anti-CD4 and CD3 Abs
and the purity was . 98%, as revealed by FACScan.
CD81 T lymphocyte response. (a) Target cells. BALB/c mice were
injected with thioglycollate broth. On day 4, the macrophages were
isolated from the peritoneal exudate cells (PEC) by adherence on Petri
plates. The harvested cells (2  107 cells/ml) were washed 3 times with
Hank’s balanced salt solution (HBSS) and incubated at 37 8C for 3–4 h
with either free OVA, OVA entrapped in egg PC/chol or encapsulated
in yeast-lipid liposomes. The cells were again washed 3 times to remove
free antigen. This was followed by incubation with 51Cr (100 mCi/
2  107 cells) for 45–60 min at 37 8C. The cells were finally washed
with RPMI solution and were used as target cells.
(b) Cytotoxicity assay. The 51Cr-labelled macrophages/P815 cells
(5  103/well) were used as target cells. The antigen primed target cells
were incubated with CD81 T cells (effector cells isolated from the spleen of
the five mice were pooled, and used for assay) at an effector to target (E/T)
ratios of 2.5 : 1–20 : 1. The cells were incubated at 37 8C for 6 h, after
completion of incubation period, the cells were pelleted at 3000  g (15 min
at 5 8C), and the amount of 51Cr released was determined by measuring the
radioactivity in the supernatant. The experiments were performed three times
and the error bars represent standard deviation of the means from three
different experiments. The total 51Cr release was calculated by treating an
aliquot of the target cells with Triton X-100 (10% final concentration). The
spontaneous release of 51Cr in the supernatant was determined by incubating
the labelled macrophages for 6 h. An amount of auto-release was subtracted
from the total release to determine the extent of macrophage lysis. In most of
the experiments, the autorelease was less than 25%. The percentage specific
release was calculated as the (mean sample cpm-mean spontaneous cpm/
mean maximum cpm-mean spontaneous cpm)  100%.
CD41 T-cell proliferation. The CD41 T cells (2  104/well) obtained
from pool of the splenic cells of five mice from different groups, were
cultured in triplicate wells. The cells were incubated with macrophages
(6  104/well) pulsed with different doses (0.001–100 mg/ml) of free
OVA or encapsulated in egg PC/chol or yeast lipid liposomes. The
macrophages were treated with mitomycin C (50 mg/ml). The cultures
were incubated for 72 h at 37 8C/7% CO2. The cells were pulsed with 1.0
mCi[3H]-thymidine for 16 h before harvesting with an automatic cell
harvester (Skatron, Tranby, Norway). The [3H]-thymidine incorporation
was measured by a standard liquid scintillation counting method. The
results are expressed as mean cpm of triplicate cultures.
Lymphokine assays. The cultures were set up as described for Th cell
proliferation. The supernatants were collected after 48 h for estimation
of IL-2, IL-4 and interferon (IFN)-g levels. The IL-2 and IL-4 were
assayed using the HT-2 cell line, while IFN-g was estimated by its
ability to inhibit the proliferation of WEHI-279 cells [13]. The
lymphokines data were expressed as pg/ml in the culture supernatants
as computed by comparison with the standard curve plotted using r IL-
2/rIL-4 and rIFN-g (Genzyme, Cambridge, MA, USA).
Determination of OVA-specific IgG isotypes by ELISA. The
production of OVA-specific antibodies was measured in the sera of
the different groups of mice. The animals were injected, intravenously,
with two doses of free OVA, OVA entrapped in the egg PC/chol or
yeast lipid liposomes (100 mg OVA/animal) on day 0 and 7, and bled on
day 14 to monitor the presence of antibodies as described earlier [13].
Briefly, 96 well microtitre plate was incubated overnight with 50 ml of
OVA (25 mg/ml) in carbonate-bicarbonate buffer (0.05 m, pH 9.6) at
4 8C. After the usual washing and blocking steps the plate was finally
incubated with 1 : 500 dilutions of test and control sera at 37 8C for 2 h.
After excessive washing of the plate, it was further incubated with
50 ml of biotinylated goat antimouse IgG1 and IgG2a antibodies. The
plate was incubated at 37 8C for 1 h. After the usual washing steps,
50 ml of streptavidin-HRP were added to each well and the plate was
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incubated at 37 8C for 1 h. The plate was washed again before adding
50 ml ABTS (Sigma) and was finally incubated at 37 8C for 20 min.
The reaction was terminated by the addition of 50 ml of 70% H2SO4.
The absorbance was read at 492 nm with a microtitre plate reader
(Eurogenetics, Torino, Italy).
Statistical analysis. The data were analyzed by one-way analysis of
variance (anova) following Dunnet’s t-test method. P , 0.05 was
considered statistically significant.
RESULTS
Delivery of the antigen entrapped in the fusogenic yeast-lipid
liposomes elicits effective immune response
CD81 T-lymphocyte response. Since our preliminary
experiments demonstrated that the yeast-lipids liposomes
possess a strong fusogenic character, the protein entrapped in
liposomes, in principle, should be delivered into the cytosol of
APCs for presentation via the MHC class I pathway. We
evaluated the potential of yeast-lipid liposomes entrapped OVA,
to undergo MHC-I processing and presentation to generate a
CD81 T-cell response. Initially the animals were immunized with
different doses of antigen entrapped in yeast liposomes (10–
100 mg OVA/per dose/per animal/total three doses, each at week
interval). It was found that a dose of 100 mg per animal induced
cytotoxic T lympocyte (CTL) response, which generated 30–40%
target lysis at an effector to target ratio of 10 : 1 (data not shown).
This dose was selected for subsequent studies performed for 51Cr
release assay. Interestingly, immunization with OVA entrapped in
the yeast-lipid liposomes, but not other forms of OVA viz. free
OVA or OVA entrapped in egg PC/chol liposomes and free OVA
mixed with yeast-lipid empty liposomes (sham liposomes),
generated cytotoxic T cells. A considerably high degree (30–
40%) of macrophage lysis occurred when the OVA was
encapsulated in the yeast-lipid liposomes, as compared to less
than 1% specific lysis in free OVA or OVA incorporated into the
egg PC/chol liposomes or sham yeast-lipid liposomes
(P , 0.001) (Fig. 1A). We also found concentration optima for
antigen (Fig. 1B) for percentage specific lysis of the target cells.
Fig. 1. (A) Induction of antigen specific cytotoxic T lympocyte (CTL)
activity by immunization with yeast lipid liposomes containing different
forms of ovalbumin (OVA). The BALB/c mice were immunized with
saline (A); Sham yeast liposomes (Sham YL)(O); Free OVA (P); yeast
liposomes mixed with OVA (YL 1 OVA) (B); OVA encapsulated in
Egg PC liposomes (PC-OVA) (X) and OVA encapsulated in yeast
liposomes (YL-OVA) (O), as described in Materials and Methods. The
effector cells were isolated from the spleen of five mice, belonging to
the different groups above. The cells were pooled, purified and used for
target cell lysis assay. The target cells (macrophages) were pulsed with
saline, Sham ES, Free OVA, Yeast liposomes mixed with OVA
(YL 1 OVA), OVA encapsulated in Egg PC liposomes (PC-LIP-OVA)
and OVA encapsulated in YL liposomes (YL-LIP-OVA), respectively
(30 mg OVA/2  107 cells), and labelled with 51Cr. The lytic activity
was measured by the incubation of suitable effector cells with target
cells (primed with matching formulation of OVA). The results are
represented as, percent specific lysis (51Cr release) of the target cells.
Each value represents the mean of three determinations ^ S.D. Data are
representative of five independent experiments performed with similar
results. (B) Dose response of antigen on the induction of target cell
lysis. The macrophages were sensitized with different concentrations of
free OVA, OVA loaded in either egg PC/chol liposomes (PC-OVA) or
yeast lipids liposomes (YL-OVA) and then incubated with OVA
reactive CD81 T lymphocytes isolated from the animals immunized
with OVA, PC-OVA, and YL-OVA, respectively. The E/T ratio was
10 : 1. In the case of control wells, target cells incubated with effector
cells (OVA reactive CD81 T cells) in the absence of antigen or with
sham liposomes (no antigen), YL mixed with OVA and unrelated
antigen (lysozyme entrapped in yeast lipids liposomes), there was not
more than 2% of 51Cr release. Values represent the mean of three
determinations ^S.D. The experiment was performed three times with
similar results.
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Results shown in Fig. 2(A) confirm the phenotype of the
effector cells. The pretreatment of the purified effector cells
with anti-CD81 antibodies, followed by treatment with baby
rabbit complement, abolished target cell lysis. We further
demonstrated that macrophages, primed with free or egg PC
liposomes encapsulated OVA, can not act as target cells
(Fig. 2B). The effector cells, obtained from the animals
immunized with yeast lipid liposomes, were allowed to incubate
with the target cells, which were primed with different forms of
OVA, i.e. the free OVA, OVA encapsulated either in egg PC
liposomes or yeast liposomes. The 51Cr release assay shows that
OVA-specific CTL successfully distinguished the target cells,
which were incubated with yeast lipid liposomes for antigen
presentation, however, egg PC liposomes pulsed target cells
were not recognized by the same CTLs (P , 0.001).
The results discussed in Table 1 demonstrated that, beside
macrophages, yeast lipid induced effector cells can lyse other
target cells with equal propensity. However, the recognition of
target cells is confined to the MHC compatible cells only, thus,
effector cells were able to induce lysis of P815, an MHC
matched (H-2d) mastocytoma cells, while allogenic EL-4 cells
(H-2b) were not recognized at all by the same effector cells.
CD41 T-cell response
Antigen entrapped in the yeast-lipid liposomes enhances
CD41 T cells proliferation. The T cells of the mice immunized
with antigen encapsulated in the yeast-lipid liposomes induced
significantly higher proliferation as compared to T cells
obtained from animals immunized with egg PC/chol liposomes
(Fig. 3). T-cell responsiveness to antigen was observed in a
dose-dependent manner. Control cultures containing cells
obtained from either OVA-immunized animals or the groups
immunized with PBS or fusogenic lipids only (sham liposomes
with no OVA), gave background levels of , 2000 cpm of 3H-
thymidine incorporation.
Antigen encapsulated into yeast-lipid liposomes
predominantly enhances the production of IL-4. The animals
immunized with single dose of antigen encapsulated in the
yeast-lipid liposomes showed significantly higher levels of IL-4
(512 pg/ml) as compared to animals inoculated with egg PC
liposomes (216 pg/ml) (Fig. 4A). In contrast, only marginal
secretions of IL-2 and IFN-g were observed when yeast-lipid
liposomes (26 pg/ml IL-2, 20.27 pg/ml IFN-g) and egg PC/chol
liposomes (12.4 pg/ml IL-2, 15.69 pg/ml IFN-g) were used for
immunization (Fig. 4B,C). No detectable amount of
lymphokines was observed in the case of control animals
inoculated either with PBS, sham egg PC/chol or yeast-lipid-
liposomes alone (no antigen). However, the animals which were
Fig. 2. (A) OVA encapsulated in yeast lipid liposome can induce T
lymphocytes with CD81 phenotype. Effector cells obtained from the
OVA (encapsulated in yeast liposomes) primed animals were pretreated
with anti-CD41 or anti-CD81 monoclonal antibodies (MoAbs) followed
by incubation with baby rabbit complement. The effector cells were
incubated with peptide pulsed, 51Cr loaded target cells. The lysis of the
target cells was measured by 51Cr release assay. Anti-CD81 antibody
pretreatment (X); anti-CD41 antibody pretreatment (B); pretreatment
with complement alone (O); and no pretreatment (D). Values are mean of
three determinations ^S.D. Data are representative of five different
experiments with similar results. (B) Yeast liposomes provide an efficient
means of sensitizing target cells to class I restricted CTL recognition.
BALB/c mice were immunized with OVA encapsulated in yeast
liposomes. Cytotoxic T cells from the spleen of five mice were pooled,
and used as effector cells for cytotoxic assay. The target cells were
primed with various formulations of OVA viz. free OVA (X); OVA
encapsulated in egg PC liposomes (7); and OVA encapsulated in yeast
lipid liposomes (B) and incubated with effector cells, isolated from YL-
OVA treated animals (at the effector to target ratio of 10 : 1). The lysis of
the target cells was measured by 51Cr release assay. Data are mean of
three determinations ^S.D.
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boosted three times with YL liposomes demonstrated a
substantial increase in the IL-2 and IFN-g level, while the IL-
4 level had decreased to some extent (Fig. 4).
Humoral immune response
Enhancement of the secretion of IgG1 isotype by immunizing
the animals with the antigen encapsulated in the liposomes of
the fusogenic lipids derived from yeast. The significant increase
in the level of antibodies was detected in sera of the animals,
which were primed with OVA entrapped in the yeast-lipid-
liposomes as compared to the animals, inoculated with egg PC/
chol liposomes (Fig. 5). However, mainly IgG1 antibodies were
generated in both the cases, while the IgG2a type of antibody
were induced to lesser extent only (P , 0.05). No IgG1 and
IgG2a isotypes were detected in the control group of mice
injected with either sham yeast-lipid/egg PC/chol liposomes (no
antigen) or PBS.
DISCUSSION
Protective immunity against intracellular pathogens (e.g.
tuberculosis, leprosy, leishmaniasis, malaria, viruses, etc.) and
cancer is considered to be controlled essentially by cell-
mediated immunity. The important role of CD41 and CD81 T
lymphocytes has been suggested by several studies of murine
and human infections [6, 7, 14, 15]. The majority of the vaccines
available to date, mainly induce the humoral immune responses,
conversely the generation of cytotoxic T cells always remains a
major uphill task against most of the infections. Earlier
investigators have attempted the use of virosomes as well as
pH-sensitive liposomes for delivery of protein antigens into the
cytosol [16–19]. Nevertheless, such vehicles proved to be toxic
to the host and were additionally not simple to prepare, and were
thus restricting their use as a vehicle to deliver the newer
generation of vaccines against intracellular infections.
We have shown earlier that the antigen incorporated into
liposomes results in the increased production of IL-4 but not
IFN-g [20]. In another report, we recently demonstrated that
yeast liposomes can readily deliver their contents to cytosol of
the APCs [8]. In the present study, we considered it to be of
interest to exploit the inherent membrane–membrane fusion
tendency of yeast lipids in the development of liposome-based
vaccines. The antigen encapsulated in liposome was allowed to
interact with the APCs. The following four major findings have
emerged from the study. Firstly, the antigen entrapped in the
yeast-lipid vehicles effectively delivers the contents into the
class I and class II antigen processing pathways; secondly, the
effector CD81 cytotoxic T cells were stimulated; thirdly, CD41
T-helper cells, predominantly of Th2 phenotype, were gener-
ated; fourthly, a predominant secretion of IgG1 isotype was
observed.
The results of the present study demonstrate that the
Table 1. Antigen specificity and MHC restriction of the OVA specific
cytotoxic T lymphocytes
Targets Treatment Specific lysis (%)
P815 None 0.45 ^ 0.12
P815 Free OVA 0.30 ^ 0.10
P815 Sham YL* 0.48 ^ 0.13
P815 YL 1 OVA† 0.54 ^ 0.09
P815 PC-OVA 0.78 ^ 0.20
P815 YL-OVA‡ 38.5 ^ 2.20
P815 YL-Lysozyme 0.65 ^ 0.15
EL-4 Free OVA 0.52 ^ 0.10
EL-4 PC-OVA 0.65 ^ 0.18
EL-4 YL-OVA 0.42 ^ 0.08
EL-4 YL-Lysozyme 0.42 ^ 0.10
The BALB/c mice were immunized with yeast liposome encapsulated
OVA, and effector cells were isolated and purified as described in the
text. The MHC restriction as well as antigen specificity of the generated
CTLs was demonstrated by 51Cr release assay. The target cells, P815
(H-2d) and EL-4 (H-2b) were pulsed with different forms of OVA and
lysozyme (an unrelated antigen) followed by 51Cr labelling, as
described in Materials and Methods. The antigen primed target cells
were incubated with effector cells at effector to target ratio of 10 : 1.
Each value represents mean of three determinations ^ SD. The
experiment was performed four times with similar results.* Liposome
without antigen; †yeast liposome simply mixed with OVA; ‡OVA
encapsulated in yeast liposomes.
Fig. 3. Antigen incorporated in yeast-lipid-liposomes augmented the
proliferation of OVA-specific Th cells. CD41 T cells (2  104/well)
were isolated from the groups of five animals immunized with OVA
encapsulated either in yeast-lipid-liposomes (YL-OVA) or egg-PC/chol
liposomes (PC-OVA) and cultured with the OVA, YL-OVA and
PC-OVA pulsed macrophages (6  104 cells/well). After 72 h,
[3H]-thymidine was added, and its incorporation was measured 16 h later
by liquid scintillation spectroscopy. The control cultures consisting of Th
cells 1 medium (no OVA), macrophages 1 medium, Th cells 1 yeast-
lipid sham liposomes (no OVA), medium 1 Th cells obtained from the
animals immunized with placebo (phosphate-buffered saline) showed
, 2000 cpm. The data represents mean cpm of three determinations
^S.D. The experiment was repeated four times with similar results.
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immunogenicity of OVA is controlled by the nature of adjuvant/
antigen carrier used for immunization (Fig. 1A). While the
antigen entrapped in the yeast lipid liposomes elicits antigen
specific CTL generation, other forms of antigen, e.g. OVA
entrapped in egg PC liposomes fail to do so. Furthermore, the
processing and presentation depends on the mode of the antigen
delivery, as evident from our results that OVA specific CTLs,
obtained from animals immunized with yeast liposomes, can
induce lysis of target cells which were primed in vitro with yeast
liposomes. The same effector cells do not lyse target cells,
which were primed in vitro with egg PC liposomes or free OVA
(Fig. 2B). In other words, these experiments prove that target
cells primed with OVA encapsulated in egg PC liposomes can
not be recognized by effector cells, i.e. OVA specific CTLs
isolated from mice immunized with OVA encapsulated in yeast
liposomes.
One can argue that macrophages can not be ideal APCs for
determining the lytic activity of the CTLs, especially for
conventional egg PC liposomes. In order to rule this possibility
out, we repeated the same study using dendritic as well as
syngenic P815 cells as APCs for performing the CTL assay. We
found that the OVA-YL primed P815 cell, in manner similar to
macrophages, can be specifically lysed by the OVA specific
effector cells. These results also demonstrate the MHC-resticted
lysis of the target cells, as MHC mismatched allogenic targets
(EL-4 cells) were not identified by same effector cells.
Furthermore, the CTL response was antigen specific, as the
target cells which were primed with lysozyme (an unrelated
antigen) were not recognized by the OVA specific CTLs
(Table 1).
To confirm the phenotype of the effector cells, these were
pretreated with anti CD81 antibodies, before using them for
51Cr release assay. The result shows that such pretreatment
abolish CTL response, which confirms the CD81 phenotype of
the generated T lymphocytes (Fig. 2A). Typical of the effector
cell mediated target lysis, the 51Cr release assay depends on the
concentration of antigen, used for the in vitro antigen
presentation (Fig. 1B).
Moreover, the results of the present study, in conformity with
the earlier reports, show that endocytosis of the antigen and
generation of CD41 T-cell response is the only predominant
Fig. 4. OVA loaded liposomes prepared from fusogenic lipids of yeast
enhances IL-4 level. The cultures were set as mentioned in the legend to
Fig. 3. The levels of different lymphokines were monitored in the
following manner. (A) The interleukin (IL)-2 content in culture SN was
measured by its ability to induce the proliferation of HT-2 cells. The
cells were incubated in 96 well plate (1  104/well) in the presence of
culture SNs (treated with anti IL-4 antibody [11B11, 1 mg/ml] to block
IL-4), for 16 h at 37 8C, pulsed with 0.5 mCi[3H]-thymidine and
harvested 8 h later. The thymidine incorporation was measured by
liquid scintillation spectrometry. The IL-2 content was computed from
standard plot of rIL-2, and expressed as pg/ml. (B) The IL-4 content
was determined using same method as for that of IL-2, except that here,
IL-2 was neutralized by anti-IL-2 MoAb (cocktail of 1 : 12 dilution of
culture SN of CRL 1698, HB 8794 and TIB 222). The proliferation of
HT-2 was assayed in similar manner and data were computed with the
standard plot of rIL-4. All data were calculated from the mean cpm of
triplicate observations and expressed as pg/ml ^ S.D., after back
calculation. (C) The secretion of IFN-g was measured by its ability to
inhibit the proliferation of WEHI-279 cells. The data are computed in
manner similar to that of IL-2, and represented as mean of triplicate
observations ^S.D. Data are representative of three different
experiments performed with similar results.
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mode, when egg PC liposomes interacts with the APC [2, 16,
17]. In contrast, the yeast lipid liposomes appear to interact with
the target cells by both endocytosis as well as membrane fusion
mode. Thus, this helps in the activation of not only CD41 T-
helper cells but also CD81 cytotoxic T cells. It is worth to
mention here that the CD41 T cell proliferative responses
generated using the yeast lipids liposomes were better than those
observed with the egg PC liposomes.
Both the CD41 T cell and CD81 T-cell responses seem to be
required for an effective control of the intracellular parasitic
infections. Current evidence suggests that in addition to T-
helper cells that activate macrophages, in fact, it is primarily the
T-cytotoxic cells, which play crucial role in the protection. Even
though, optimum levels of CD41 T-cell response were
generated, yet the disease develops in the absence of CTL cells
[5, 6]. Thus, encapsulation of the protective antigens in the yeast
lipids liposomes may elicit strong CTL response that may be
necessary for protection against intracellular infections.
Furthermore, the use of yeast liposomes leads to the
generation of Th2 cells and CTLs. Th2 cells are known to
provide help to B cells leading to the production of antibodies,
while Th1 cells are crucial for the activation of the CTLs [9].
The Th1/Th2 shift is crucial to the effective immunity and it is
likely that many interlocking factors will contribute to that
decision [7]. The yeast liposome mediated strong CTL
generation, in spite of the observed polarization of the CD41
T-cell response in favour of the Th2 cells that can be attributed
to the physical targeting of the entrapped antigen to the cytosol
of the APCs. The yeast liposomes like other particulate
substances are avidly endocytosed by APCs and activate
CD41 T cell. However, it can not be excluded that in addition
to the endocytosis, a substantial portion of the entrapped antigen
is delivered to the cytosol of the target cells, and form the basis
of the observed antigen specific CTL response. The peculiar
behaviour of the yeast lipid liposome based delivery system,
might function in a way that could be a more desirable feature in
activation of both cell mediated as well as humoral immune
responses. Such a strategy could be appropriate for elimination
of virus mediated infections. It is a well known fact that both
CTLs and the neutralizing antibodies are essential for imparting
protective immunity against the viruses as well as other
pathogens [5, 6, 21, 22].
It may be inferred from our study that the lipids derived from
S. cerevisiae possess a strong fusogenic character. The yeast
lipid liposomes can effectively deliver antigen into the class I
and class II processing compartments of APCs and consequently
generating a strong antigen-specific CD81 (cytotoxic) and
CD41 (helper) T cells. Such considerations, which could
selectively enhance the CTL and the T-helper cells are pertinent
in designing liposomes-based vaccines, and will hence subserve
in the protection against infectious diseases.
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